Comparative Pharmacology
Head-to-head clinical analysis: AMIKIN versus NEOMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKIN versus NEOMYCIN SULFATE.
AMIKIN vs NEOMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing bacterial cell death by disrupting the cytoplasmic membrane.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
1-2 g orally 4 times daily (8-16 g/day) for hepatic encephalopathy or intraluminal infection; 0.5-1 g orally 4 times daily for preoperative bowel preparation.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
2-3 hours (normal renal function); prolonged to 20-60 hours in anuria
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Renal (glomerular filtration) >90% unchanged; small amount biliary/fecal (<3%)
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic